Christian Harding | CSO & Co-founder
Omniose

Dr. Harding is the primary founder of Omniose dating back to 2017 when he left his academic position to lead company formation, laboratory space development, and research activities. He is the main innovator and driver for all Omniose R&D activities, including its bioconjugation platform. Dr. Harding has refined Omniose’s bioconjugation technology for use in developing bioconjugate vaccines against multiple bacterial targets, including, Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae. He has devised eight awarded SBIR/STTR grants totaling more than $14M in non-dilutive funding, fueling Omniose’s R&D pipeline and company growth. In addition, he has authored numerous peer-reviewed manuscripts in distinguished journals and is the inventor of 11 different patent families encompassing methods of use and composition of matters pertaining to Omniose’s bioconjugation technology.

Dr. Harding conducted his Postdoctoral Fellowship under Dr. Mario Feldman’s mentorship at Washington University in St. Louis focusing on microbial glycobiology. He earned his Ph.D. in Biomedical Sciences from The Ohio State University and a B.S. from the College of Charleston in Charleston, South Carolina.

He currently serves on the Klebsiella pneumoniae Working Group of the World Health Organization Collaborative Open Research Consortium on priority bacterial pathogens.